Investigation of GlobeImmune, Inc. Announced by Glancy Prongay & Murray LLP

Glancy Prongay & Murray LLP announces that it is investigating potential claims on behalf of investors of GlobeImmune, Inc. (“GlobeImmune” or the “Company”) (NASDAQ:GBIM) concerning the Company’s and its officers’ possible violations of federal securities laws.

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that the Company’s working capital would be insufficient to support the Company’s continuing operations, in light of failures with the Company’s FDA clinical trials for GlobeImmune’s therapeutic products. As a result of the Company’s fraudulent conduct investors have been severely damaged.

On May 27, 2015, the Company announced top line results from the Phase 2 trial for its hepatitis B treatment. On news that the Company’s hepatitis B treatment failed to meet the trial’s primary endpoint, shares of GlobeImmune fell by $4.23 per share, or over 50%, to close on May 27, 2015 at $4.01 per share. Then, on June 10, 2015, GlobeImmune announced that, “it is evaluating strategic options for the company. In conjunction with this process, the Board has authorized eliminating the majority of positions in its workforce. . . Following our recent data announcement in our hepatitis B program, this workforce reduction is a necessary action to conserve working capital and provide maximum flexibility in determining the future direction of GlobeImmune.” On this news, shares of GlobeImmune fell $1.00 per share, during intraday trading on June 10, 2015, or more than 26%.

If you purchased shares of GlobeImmune prior to June 10, 2015, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150610006115/en/